BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 532 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $486,862 | +2.0% | 6,795 | +0.3% | 0.01% | 0.0% |
Q1 2024 | $477,103 | -9.9% | 6,778 | -1.2% | 0.01% | -22.2% |
Q4 2023 | $529,549 | +5.6% | 6,863 | -6.8% | 0.01% | -10.0% |
Q3 2023 | $501,336 | -18.0% | 7,365 | -1.7% | 0.01% | -9.1% |
Q2 2023 | $611,327 | +22.3% | 7,489 | +11.1% | 0.01% | +10.0% |
Q1 2023 | $499,966 | -8.7% | 6,739 | +2.0% | 0.01% | -9.1% |
Q4 2022 | $547,671 | +62.0% | 6,608 | +454.8% | 0.01% | +57.1% |
Q3 2022 | $338,000 | -19.3% | 1,191 | -1.5% | 0.01% | -12.5% |
Q2 2022 | $419,000 | -23.5% | 1,209 | -4.4% | 0.01% | -11.1% |
Q1 2022 | $548,000 | -13.4% | 1,265 | +3.3% | 0.01% | -10.0% |
Q4 2021 | $633,000 | +15.3% | 1,224 | +8.0% | 0.01% | +25.0% |
Q3 2021 | $549,000 | +16.8% | 1,133 | +8.6% | 0.01% | +14.3% |
Q2 2021 | $470,000 | +27.4% | 1,043 | +8.0% | 0.01% | +16.7% |
Q1 2021 | $369,000 | -20.5% | 966 | -33.9% | 0.01% | -25.0% |
Q4 2020 | $464,000 | +37.7% | 1,462 | +7.3% | 0.01% | +14.3% |
Q3 2020 | $337,000 | +53.2% | 1,362 | +63.7% | 0.01% | +40.0% |
Q2 2020 | $220,000 | +39.2% | 832 | +0.1% | 0.01% | +25.0% |
Q1 2020 | $158,000 | -12.2% | 831 | +1.6% | 0.00% | 0.0% |
Q4 2019 | $180,000 | -50.3% | 818 | -55.8% | 0.00% | -50.0% |
Q3 2019 | $362,000 | -5.5% | 1,852 | +0.9% | 0.01% | -11.1% |
Q2 2019 | $383,000 | -2.8% | 1,835 | -7.6% | 0.01% | 0.0% |
Q1 2019 | $394,000 | +39.7% | 1,986 | +1.8% | 0.01% | +12.5% |
Q4 2018 | $282,000 | -43.1% | 1,950 | -19.7% | 0.01% | -33.3% |
Q3 2018 | $496,000 | +59.0% | 2,428 | +15.3% | 0.01% | +33.3% |
Q2 2018 | $312,000 | +5.1% | 2,106 | +7.1% | 0.01% | -18.2% |
Q1 2018 | $297,000 | +403.4% | 1,967 | +331.4% | 0.01% | +450.0% |
Q4 2017 | $59,000 | +20.4% | 456 | +12.0% | 0.00% | 0.0% |
Q3 2017 | $49,000 | – | 407 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |